The potential market for complex generics is substantial, but navigating the FDA’s guidance for proving “sameness” is a real minefield...
Bérangère Tissot | | Opinion
Generic medicines are now an established part of the pharmaceutical supply chain and offer significant savings to health services, insurers and patients alike. More recently, biosimilars have entered the fray, and while the savings are not as great as with small molecule generics, they still help cut the costs of medicine. However, there is also a third category of product that falls between the two – the complex generic. These are products that may include complex: active ingredients, formulation, route of delivery, or even a mixture of ingredients.
Read the full article now
Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Analytical Scientist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.